Drug Profile
MK 1064
Alternative Names: MK1064Latest Information Update: 19 Sep 2015
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Amides; Pyridines; Sleep disorder therapies; Small molecules
- Mechanism of Action Orexin receptor type 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Insomnia